NASDAQ:KNSA Kiniksa Pharmaceuticals International Q3 2026 Earnings Results & Report $93.88 +0.34 (+0.37%) As of 03:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Kiniksa Pharmaceuticals International beat analyst expectations on both earnings and revenue in its Q3 2026 results, released October 27, 2026. The company reported EPS of $0.56 versus the $0.3710 consensus estimate, while revenue of $285.97 million topped the $260.66 million estimate by $25.31 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateOctober 27, 2026TimeBefore Market OpensConference Call8:30 AM ET Kiniksa Pharmaceuticals International EPS ResultsActual EPS$0.56Consensus EPS $0.3710Beat/MissBeat by +$0.1890One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersKiniksa Pharmaceuticals International Revenue ResultsActual Revenue$285.97 millionExpected Revenue$260.66 millionBeat/MissBeat by +$25.31 millionYoY Revenue GrowthN/AConference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Kiniksa Pharmaceuticals International Q3 2026 Earnings Call TranscriptProvided by QuartrOctober 27, 2026ShareShareShare This ReportLink copied to clipboard.Key Takeaways Positive Sentiment: 2026 revenue guidance was raised to $1.045–$1.050 billion, with third-quarter ARCALYST revenue up 58% year over year to $286 million. Operating income reached $54.2 million and net income $47.3 million. Positive Sentiment: ARCALYST penetration among the approximately 14,000 annual patients with multiple recurrences reached 23% at quarter-end, up from 18% at the end of 2025. Kiniksa reported about 5,450 prescribers, growing interest in earlier treatment, and strong initial engagement with its targeted Heart’s Home campaign. Positive Sentiment: The company said its profitable ARCALYST business generated approximately $43 million of net cash during the quarter, leaving $568.8 million in cash to fund commercialization, clinical development, and potential value-creating opportunities. Neutral Sentiment: KPL-387’s pivotal Phase III trial continues to enroll and dose patients, with data now expected in the second half of 2027 and a potential launch targeted for 2028–2029. KPL-1161, a potential quarterly IL-1 inhibitor, remains on track to enter Phase I by year-end, although its initial indication has not been disclosed. AI Generated. May Contain Errors.Conference Call Audio Live Call not available Earnings Conference CallKiniksa Pharmaceuticals International Q3 202600:00 / 00:00Speed:1x1.25x1.5x2xTranscript SectionsPresentationParticipantsPresentationSkip to Participants Operator00:00:00Thanks for standing by, and welcome to the Kiniksa Pharmaceuticals Third Quarter 2026 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you'll need to press star one one on your telephone. If your question has been answered and you'd like to remove yourself from the queue, simply press star one one again. As a reminder, today's program is being recorded. Now I'd like to introduce your host for today's program, Jonathan Kirshenbaum, Investor Relations. Please go ahead, sir. Jonathan KirshenbaumSenior Manager of Investor Relations at Kiniksa Pharmaceuticals International00:00:35Thank you, operator. Good morning, everyone, and welcome to the Kiniksa Pharmaceuticals Third Quarter 2026 Earnings Call. A press release highlighting our financial results and recent portfolio execution can be found on our website under the Investors section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. Jonathan KirshenbaumSenior Manager of Investor Relations at Kiniksa Pharmaceuticals International00:00:58From there, Ross Moat, our Chief Operating Officer, will provide an update on ARCALYST commercial execution. After that, Mark Ragosa, our Chief Financial Officer, will review our third quarter 2026 financial results. Finally, Sanj will return at the end of the call to share closing remarks and kick off the Q&A session, for which John Paolini, Kiniksa's Chief Medical Officer, will also be on the line. Jonathan KirshenbaumSenior Manager of Investor Relations at Kiniksa Pharmaceuticals International00:01:26Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from such statements. A review of these statements and risk factors can be found on this slide, as well as under the caption Risk Factors contained in our SEC filings. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements except as required by law. With that, I'll turn it over to Sanj. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:01:57Thanks, Jonathan, and good morning or good afternoon, everyone. Over the last 10, 11 years, we've built this company through multiple stages of growth, and today, I'm as excited as ever about what the team and I can accomplish together in the years ahead. Kiniksa continues to build a leading IL-1 alpha and beta inhibition franchise driven by the commercialization of ARCALYST in recurrent pericarditis, as well as our progress with KPL-387 and KPL-1161. This morning, we announced via a press release that we've raised our full-year revenue guidance to between $1.045 billion and $1.050 billion. We continue to see robust growth with ARCALYST in recurrent pericarditis, driven by strong execution and strategic investments across the business. On the clinical side, we're excited about the progress of KPL-387 and KPL-1161. The pivotal phase III study with KPL-387 continues to enroll and dose patients. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:03:13We announced today that we expect data from this trial in the second half of 2027. The team and I are really looking forward to potentially launching this drug in the 2028, 2029 timeframe. In addition to providing an important treatment option for patients with recurrent pericarditis, we believe KPL-387 could help grow the market by enabling a once-monthly subQ dosing. We are also on track to have KPL-1161, our quarterly IL-1 alpha and beta inhibitor, in a phase I clinical trial by the end of this year. Importantly, Kiniksa's robust financial profile allows us to continue to invest in penetrating the recurrent pericarditis market and growing the IL-1 alpha and beta inhibition franchise whilst also pursuing additional value-creating opportunities. In the third quarter, we saw a continuation of strong ARCALYST momentum with Q3 revenue of $286 million. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:04:26The penetration rate into the annual population of 14,000 multiple recurrence patients increased to 23% as of the end of Q3. As shown by the increased breadth and depth of prescribing over time, adoption of IL-1 alpha and beta inhibition continues to expand among the approximately 40,000 recurrent pericarditis patients each year. The underlying fundamentals that propelled our commercial success remain strong. Since launch, we have observed robust payer approval, strong patient compliance, and greater appreciation of the need to treat throughout the multi-year duration of the disease. Underpinning this growth is strong execution by our commercial organization and data-driven investments in ARCALYST. Our AI-supported patient identification initiatives and targeted direct consumer campaign, Heart's Home, have positively contributed to growing patient and physician awareness of recurrent pericarditis and the important role of IL-1 alpha and beta inhibition in controlling this debilitating disease. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:05:56As you have heard, we now expect ARCALYST to achieve over $1 billion in revenue in 2026 and we look forward to continuing to bring this blockbuster drug to more patients suffering from this debilitating disease. In order to grow the recurrent pericarditis market over the next several years, we plan to drive greater adoption in both the 14,000 multiple recurrence patients annually and the additional 26,000 patients annually that are experiencing their first recurrence. Kiniksa is executing against its strategy to help more patients drive more ARCALYST growth and advance KPL-387 and KPL-1161. This trajectory will help put the company on a path to having multiple commercial products, continued strong and profitable growth, and the flexibility to invest in future value creation. I can tell you that the team and I will not rest until we have helped many, many more patients. Now our President and COO, Ross Moat. Ross MoatCOO at Kiniksa Pharmaceuticals International00:07:17Thank you, Sanj. As you have heard, we are pleased with the continued strength of our commercial performance with ARCALYST, and we are even more excited by the substantial growth opportunity ahead. We continue to be highly focused on further increasing the penetration rate into the many thousands of recurrent pericarditis patients and continuing to evolve the treatment paradigm towards interleukin-1 alpha and beta inhibition. As illustrated on the left side of this slide, physicians continue to report an increasing consideration of ARCALYST earlier in the disease course, including at the first recurrence. Additionally, we also see a growing appreciation for ARCALYST to be utilized earlier in the line of therapy, meaning after NSAIDs and colchicine, and importantly, prior to corticosteroids, as ratified in the 2025 American College of Cardiology Concise Clinical Guidance for Recurrent Pericarditis. Ross MoatCOO at Kiniksa Pharmaceuticals International00:08:24In fact, approximately 50% of physicians surveyed now support this treatment approach, representing a doubling from levels over the last three years prior to the publication of this independent guidance. As we continue to build and lead this market, our team are laser-focused on value-driven investments that aim to increase market penetration and help many more patients. Increasing education and awareness on recurrent pericarditis, ARCALYST, and the new treatment paradigm remain critical components of our strategy, and we've enhanced our capabilities through the use of AI and machine learning to reach a larger audience. On the healthcare professional side, we've done this through improving our data sources to inform us not only which healthcare professionals we should be seeing, but importantly, when we should be seeing them. On the patient side, we've seen encouraging early indicators from our Heart's Home direct-to-consumer campaign. Ross MoatCOO at Kiniksa Pharmaceuticals International00:09:37Based on this initial traction, we plan to expand the campaign with additional content and outreach initiatives aimed at empowering more patients to engage with their healthcare professionals about ARCALYST. As a reminder, Heart's Home is a highly targeted DTC campaign where we've innovated from traditional DTC by using AI to produce and deliver a campaign that's effective for a rare disease audience. This campaign is aimed at educating an enriched population of likely recurrent pericarditis patients who are currently not taking ARCALYST and empowering them to discuss ARCALYST with their healthcare provider. As an early indicator of the impact of this campaign, we've seen a twelvefold increase in the traffic to our ARCALYST website compared to baseline levels prior to the campaign. Additionally, there's been an eightfold increase with engaged sessions, meaning visits where the individual spends meaningful time on the website or interacts with the content. Ross MoatCOO at Kiniksa Pharmaceuticals International00:10:51More importantly, approximately 55% of patients who saw the ad strongly agreed that they are motivated to speak with their healthcare provider about ARCALYST. All of these indicators are strong signals that our digital strategy is reaching the right audience and is empowering action. As this disease has a very high annual incident rate of patients coming into the labeled indication, this DTC initiative is nicely supplementing our robust execution in the field and helps us to address the substantial opportunity that we have ahead to help many more patients. As previously mentioned, our interleukin-1 alpha and beta inhibition franchise is growing, is profitable, and has significant opportunity in the months and years ahead. With that, I'll turn the call over to Mark to review our financial results. Mark RagosaCFO at Kiniksa Pharmaceuticals International00:11:56Thanks, Ross. Our third quarter delivered continued ARCALYST sales growth, advancement of KPL-387 and KPL-1161 development, and a solid financial position. This morning, I'll review our financial results and key performance drivers. Mark RagosaCFO at Kiniksa Pharmaceuticals International00:12:12Detailed financial information is available in today's press release. Starting with the income statement, ARCALYST revenue grew 58% year-over-year to $286 million in the third quarter, driven by continued gains in patient and physician adoption. Operating expenses increased year-over-year, driven by higher ARCALYST revenue, which resulted in additional cost of goods sold and collaboration expenses, advancement of KPL-387 development, which drove additional R&D investment, and support of ARCALYST commercialization to reach more patients, which led to additional SG&A investment. Operating income rose to $54.2 million and net income to $47.3 million, both up significantly year-over-year. Turning to the calculation of ARCALYST collaboration profit, which drives total collaboration expenses on our income statement. ARCALYST collaboration profit increased 67% year-over-year to $211.6 million, outpacing sales growth and reflecting disciplined commercial investment. Mark RagosaCFO at Kiniksa Pharmaceuticals International00:13:20Next, we ended the third quarter with $568.8 million in cash, reflecting approximately $43 million in net cash generation during the quarter. Looking ahead, in addition to our updated 2026 ARCALYST sales guidance of $1.045 billion-$1.050 billion, we are providing full year R&D and SG&A expense guidance. We expect full year R&D expenses of $160 million-$170 million in 2026. This range includes continued development of KPL-387 and KPL-1161, as well as significant fourth quarter KPL-387 pre-commercial manufacturing costs. We expect full year SG&A expenses of $270 million-$280 million in 2026. This range supports continued ARCALYST commercialization, including additional personnel and promotional activities in the fourth quarter to further build disease awareness and enhance patient and physician targeting. Mark RagosaCFO at Kiniksa Pharmaceuticals International00:14:28In closing, our third quarter results show the strength of our operating plan, a growing and profitable ARCALYST business funding the advancement of key development assets and positioning us to create value in the near and long term. With that, I'll turn the call back to Sanj for closing remarks. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:14:47Thanks, Mark. As you've heard, Kiniksa is jolly well positioned to build significant future value as we grow our IL-1 alpha and beta inhibition franchise. The team and I are on it and focused on helping as many patients as possible with ARCALYST and to advancing the development of our clinical portfolio in order to bring additional therapies to patients. With that, I'll turn it back to the operator for questions. Thank you. Operator00:15:19Certainly. Thank you. Our first question for today comes from the line of Anupam Rama from JPMorgan. Your question, please. Anupam RamaAnalyst at JPMorgan00:15:28Hey, guys. Thanks so much for taking the question, and congrats on the quarter. I just wanted to ask a quick KPL-387 question. I think the guidance for pivotal data in the second half of 2027 is new today. Can you tell us what you're seeing in terms of enrollment dynamics and where you are on site initiation that give you confidence to laying out this timeline? Thanks so much. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:15:52Thanks, Anupam. I think I'll have John Paolini answer that. Suffice to say that our execution, across not just commercial but also the clinical development organization, as I've said before, we are enrolling and dosing patients. It's a global clinical study with global sites, and both myself, John, and Ross take pride in meeting with investigators and just getting them excited about the future. There's been some massive momentum, both internally and with our investigators. As with everything, we go at things with full force, and that's why the guidance is as well and is having results in the second half of next year. John? John PaoliniChief Medical Officer at Kiniksa Pharmaceuticals International00:16:30Yeah, I think that's excellent guidance from Sanj. The only thing that I would add is that on clinicaltrials.gov, you can see the extent of the global nature of our program. The sites that are involved in the program across the world are all listed there. You can see the scope of effort. As Sanj mentioned, we are on the ground and engaging with clinicians, and we can feel the excitement about the program, and so we continue forward. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:16:59I'll also say we have a crack clinical operations team, and having run clinical operations for many years at Genzyme before I ran commercial, I've got a very high bar for clinical research and clinical operations. And after many, many years, I feel like we've really got the best team to do the job. Anupam RamaAnalyst at JPMorgan00:17:20Thanks so much for taking our question, and congrats again on the quarter. Operator00:17:24Thank you. Our next question comes from the line of Edward Nash from Canaccord Genuity. Your question, please. Edward NashAnalyst at Canaccord Genuity00:17:31Hey, good morning, guys. Really excited to see that over $1 billion number now for the guidance. So congratulations. I just wanted to ask now, you're at 23% active penetration. That's 2% higher than last quarter, which is really, I think, impressive. Can you maybe give us an idea of how we should think about the shape of the penetration curve from here? Is there anything structurally different about the next quartile of patients versus the patients you've already converted? You're going up on the SG&A number, which makes a lot of sense, and you've put a lot of focus on the DTC campaign, which clearly seems to be paying off. Just curious as to how many extra dollars need to be put in to achieve greater uptake of scripts? Ross MoatCOO at Kiniksa Pharmaceuticals International00:18:17Thanks, Edward. This is Ross. Thanks very much for your comments. We are pleased to announce that we were around 23% at the end of the quarter in terms of penetration into the multiple recurrence group, which is the patients that have suffered for two or more recurrences, and that is without allocating anything to the first recurrence group, which we have about 20% of our prescriptions in the first recurrence group also. The opportunity is very significant. While on one hand, we are happy with the 23%, and that is obviously showing a couple of percent growth versus the end of Q2 number when we shared it the time before that. The last time we shared the penetration number, I think it was at the end of Q4, which was 18% at the end of last year. Ross MoatCOO at Kiniksa Pharmaceuticals International00:19:01That has been growing relatively nicely, but I think more importantly is the opportunity that is ahead. Clearly there are a lot of patients in the two-plus recurrence group that we have still got to help. As I said, not allocating for even those who are in the first recurrence. As we shared from some of the market research today, the propensity and the desire for physicians to look and treat patients with IL-1 alpha beta inhibition in the first group has also been growing quite substantially over time. We think the future is very bright from that perspective. In terms of different patient groups, aside from the recurrence number, there is really not much else to report. We are not seeing significant change necessary in the demographics of the patients or severity levels or anything else. It is just that this is a rare flaring cardiovascular disease. Ross MoatCOO at Kiniksa Pharmaceuticals International00:19:54There are a lot of patients out there relative to a rare disease. We are trying to get out and reach as many patients as possible. We know that they are widely dispersed around the country, and that takes a certain effort, as you have alluded to, from our sales and marketing spend and so on. Our efforts are ultimately on value-driven investments that can make sure we reach those physicians and switch more and more of them on to this new way of treating and ultimately get greater penetration into this opportunity to ultimately help more patients. Edward NashAnalyst at Canaccord Genuity00:20:34Thanks a lot for that additional coloring. I am sorry, go ahead. Ross MoatCOO at Kiniksa Pharmaceuticals International00:20:38Yeah. No, Edward, maybe just to add the final part as well is that the DTC spend and field team spend that we have, and we've announced in our guidance looking forward as well, is ultimately very efficient. We are very focused on this as a rare disease market. For the DTC side of things, this is not broad-spectrum, massive spend DTC. It's very efficient, very targeted type of expenditure to address appropriately the market that we have. Edward NashAnalyst at Canaccord Genuity00:21:09Great. Thanks for that additional color and really great quarter. Thanks again. Congratulations. Operator00:21:16Thank you. Our next question comes from the line of Paul Choi from Goldman Sachs. Your question, please. Paul ChoiAnalyst at Goldman Sachs00:21:24Hi, everyone. Congratulations on the great quarter and congrats, Ross, as well on the new title. I want to ask on the 387 switch strategy. I was wondering if you could just sort of provide a little more color on where you are with progress on that, and I guess what the ultimate data you're looking for there to support 387 from an insurance perspective. My second question is on 1161. Maybe just where are you thinking in terms of indication selection, I guess, at this point, and a little bit more on the criteria that you're considering for the first indication there for 1161. Thank you so much. John PaoliniChief Medical Officer at Kiniksa Pharmaceuticals International00:22:10Thank you, Paul. Appreciate your questions. This is John. With regard to the KPL-387 transition to monotherapy dosing and administration study, this study is designed primarily as what we call a posology study. It covers dosing administration specifically for informing the label. It's designed, as you can see in the slides, we're looking at how patients are coming from stable therapies, whether they're oral or biologic, and then transitioning to KPL-387 monotherapy at the 300 mg subcutaneous monthly dose level. That's really what that study is designed to do. It follows very similarly the precedent of what's in the ARCALYST label, which similarly describes the transitions from NSAIDs, colchicine, corticosteroids, and anakinra. This is just really following in that tradition. That's how the study is designed and the data that will be generated. John PaoliniChief Medical Officer at Kiniksa Pharmaceuticals International00:23:10I'll turn it over to Ross to talk about ultimately other elements of transition. Ross MoatCOO at Kiniksa Pharmaceuticals International00:23:16Yeah. Thanks very much, John. I guess just to say that obviously we're very excited about the potential for KPL-387. Everything's data dependent as we move forward. When we tested the target product profile for KPL-387, both with healthcare professionals and patients, we were really very encouraged by the feedback that we had back. While we believe that ARCALYST has a lot of growth left in it to address the recurrent pericarditis opportunity, with KPL-387, patients did tell us that around 75% of them would prefer the KPL-387 target profile being a monthly liquid formulation, potentially auto injector over current commercial or other investigational therapies. They also reported a propensity for a greater number of patients to start on therapy with that target product profile, as well as staying on therapy longer. Ross MoatCOO at Kiniksa Pharmaceuticals International00:24:14When you looked at the healthcare professional side, 92% of healthcare professionals indicated a high likelihood to prescribe KPL-387 with that target product profile over available commercial or other investigational therapies. That I think reads quite positively about the future, but ultimately we are focused on conducting the clinical research and awaiting the data. John PaoliniChief Medical Officer at Kiniksa Pharmaceuticals International00:24:42With regard to your question about KPL-1161, we are very excited about this program, which has the potential for once quarterly dosing, again, targeting the IL-1 alpha and beta signaling by targeting the receptor. This program we expect to begin a phase I program by the end of the year. To that extent, we have not yet announced or disclosed our plans with regard to development indications. Suffice it to say, though, that with that longer duration of action, that really unlocks a lot of potential for disease states, especially those that are chronic or lifelong in nature by virtue of the once quarterly dosing. Ross, anything to add? Ross MoatCOO at Kiniksa Pharmaceuticals International00:25:33No. That is great, John. Thank you. Paul ChoiAnalyst at Goldman Sachs00:25:34That is great. Operator00:25:38Thank you. Our next question comes from the line of Roger Song from Jefferies. Your question, please. Peter ChenAnalyst at Jefferies00:25:46All right. This is Peter. I am calling in for Roger. Congrats on a good quarter, and thanks for taking our questions. Just a couple quick ones from us. For Q3, can you tell us what share of the new patients came from first-time versus repeat prescribers? Can you also share whether or how much growth you have seen within the first recurrence patients as well for this quarter? Ross MoatCOO at Kiniksa Pharmaceuticals International00:26:10Yeah, Peter, thanks very much for the questions. We do not share some of that data directly externally, but of course it is the type of thing that we look at a lot internally in the business. What we have shared is in the Q3, clearly we have seen a substantial uplift in the number of patients representing the strong growth of nearly $42.5 million quarter-on-quarter. Ultimately, that is driven by strong prescriber growth. What we have said is that when you look at the total number of prescribers launched to date of ARCALYST for recurrent pericarditis in Q3, or I should say at the end of Q3, we had around 5,450 total prescribers. That is an uplift of around 450 quarter-on-quarter. Again, it is really showing very strong growth. Ross MoatCOO at Kiniksa Pharmaceuticals International00:27:01Now we have around 30% of that group who are repeat prescribers, which is up by around 170 prescribers. Historically, we have said that the split between the first and second recurrence is about 80% of prescriptions in the second plus recurrence and 20% in the first, but we have not updated that data on a very frequent basis, as a lot of it comes from kind of ad hoc market research that we do. Clearly we are showing pretty strong growth in Q3. A lot of that is down to the refined targeting that we have with our field team, the DTC campaign in a very targeted approach, and also just broader dissemination of the ACC concise clinical guidance and really just empowering physicians on this new way of treating the disease. Peter ChenAnalyst at Jefferies00:27:51Got it. Thanks so much for the additional color and congrats again on the quarter. Ross MoatCOO at Kiniksa Pharmaceuticals International00:27:55Thanks, Peter. Operator00:27:57Thank you. Our next question comes from the line of Geoff Meacham from Citi. Your question, please. Geoff MeachamAnalyst at Citi00:28:04Hey, guys. Great job on the quarter. Thanks for the question. Just have a couple quick ones. The first on 387, I know convenience angle obviously is a big differentiator, but beyond that, is there a patient maybe on ARCALYST today that you think is particularly suited to transition to 387 just beyond convenience? I know clinically maybe those that live further away or what are the attributes of the patients, I guess is the question that would maybe more rapidly switch? Then bigger picture question, just on the cash and the capital deployment. You guys have been consistently profitable. You are building some cash on the balance sheet. I do not know, just trying to think of ways to maximize value from a balance sheet cash flow context. What are you thinking about from a BD perspective? Where does this fall in your priorities? Thank you. John PaoliniChief Medical Officer at Kiniksa Pharmaceuticals International00:29:07Thank you, Geoff, for your question. I will tackle this first part with regard to the transition, if you will, from ARCALYST to KPL-387. I think that our position with regard to the management of the disease is that blockade of IL-1 alpha and IL-1 beta is critical to maintaining disease control and to gaining the disease control as a monotherapy. In that sense, we are particularly excited about the KPL-387 program because it adds to the optionality of what is available to patients and physicians in terms of treating this disease. That efficacy ultimately remains to be demonstrated in the phase III pivotal trial, which is ongoing. John PaoliniChief Medical Officer at Kiniksa Pharmaceuticals International00:29:52But importantly, what we have going on as well is the 212 study or the KPL-387 transition to monotherapy dosing and administration study, which is really designed to look at the mechanics of how to transition from one existing therapy to KPL-387 monotherapy at the 300 mg monthly dose level. That includes NSAIDs and colchicine, corticosteroids or IL-1 pathway inhibitors, including anakinra and rilonacept. All of those different transition regimens are studied and are evaluated in the study and then go on to over a 16-week primary endpoint period. So it's really about that transition, and that then informs the label with regard to telling or informing physicians how they can make that transition. In terms of the patient profile, it's really about the optionality for the patient and the physician to choose which effective therapy is considered to be best for them. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:31:00Geoff, in regards to your question on maximizing value and cash position, I can tell you what drives us each and every day is the potential to increase that overall maximum value. There's so much kinetic energy within the company that's focused on that. We've talked about, obviously today, the growth with ARCALYST, and we continue to be very excited about the future potential there. We talked about the latest penetration rate at being, in some ways, only 23%. Equally, obviously, across the development portfolio with KPL-387 and 1161, as we've talked about, really moving now into what obviously is a phase III pivotal study for 387, being very excited about being in the clinic with 1161 later this year. As you see, those latter two programs were homegrown. So we continue to look at other additional value-creating opportunities, both internally but also externally. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:31:51I think we've been very judicious and very thoughtful about capital allocation. We do look at BD opportunities, but as you can imagine, with our commercial products, with our pipeline, the bar is exceedingly high. That said, we're a very pragmatic bunch, and we do look at where the value could come from all the time. It's what drives us, essentially. So rest assured, we know how to capital allocate. We know where best to drive value, and we'll continue doing that and ultimately keep executing. Geoff MeachamAnalyst at Citi00:32:22Great. Thank you. Operator00:32:24Thank you. This does conclude the question and answer session of today's program. I would like to hand the program back to Sanj K. Patel, CEO, for any further remarks. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:32:34Thank you very much. Thanks, everybody, for dialing in today. Clearly a lot of excitement, ongoing execution, and very excited about the future. The team and I will keep driving for future success for patients and for creating that additional value. Thank you. Operator00:32:49Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.Read moreParticipantsExecutivesJonathan KirshenbaumSenior Manager of Investor RelationsSanj K. PatelCEORoss MoatCOOMark RagosaCFOJohn PaoliniChief Medical OfficerAnalystsAnupam RamaAnalyst at JPMorganEdward NashAnalyst at Canaccord GenuityPaul ChoiAnalyst at Goldman SachsPeter ChenAnalyst at JefferiesGeoff MeachamAnalyst at CitiPowered by Earnings DocumentsSlide DeckPress Release(8-K)Quarterly report(10-Q) Kiniksa Pharmaceuticals International Q3 2026 Earnings FAQ Did Kiniksa Pharmaceuticals International beat earnings estimates for Q3 2026? Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported earnings of $0.56 per share for Q3 2026, beating the consensus estimate of $0.3710. The report was announced on Tuesday, October 27, 2026. What was Kiniksa Pharmaceuticals International's revenue for Q3 2026? Kiniksa Pharmaceuticals International reported revenue of $285.97 million for Q3 2026, against a consensus estimate of $260.66 million. Where can I read Kiniksa Pharmaceuticals International's Q3 2026 earnings call transcript? The full Kiniksa Pharmaceuticals International Q3 2026 earnings conference call transcript is published on this page, including prepared remarks and the analyst Q&A session, along with the participants who spoke on the call. Kiniksa Pharmaceuticals International Earnings HeadlinesAre Options Traders Betting on a Big Move in Kiniksa Pharmaceuticals Stock?1 hour ago | finance.yahoo.comWhy Kiniksa Pharmaceuticals International, plc (KNSA) is a top momentum stock for the long term1 hour ago | msn.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 20 at 1:00 AM | Profits Run (Ad)TD Cowen highlights catalysts for a 2027 Best Idea stockNovember 19 at 6:06 PM | uk.finance.yahoo.comKiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Now Rated "Moderate Buy" by Wall Street AnalystsNovember 19 at 3:14 AM | americanbankingnews.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Gets Price Target Increase from TD CowenNovember 19 at 2:42 AM | americanbankingnews.comSee More Kiniksa Pharmaceuticals International Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kiniksa Pharmaceuticals International? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiniksa Pharmaceuticals International and other key companies, straight to your email. Email Address About Kiniksa Pharmaceuticals InternationalKiniksa Pharmaceuticals International (NASDAQ:KNSA) plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions. The company also develops investigational therapies for inflammatory and immune-mediated conditions, including treatments that target pathways involved in immune-cell activity. These programs are at different stages of development and may change as clinical research progresses.View Kiniksa Pharmaceuticals International ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PresentationSkip to Participants Operator00:00:00Thanks for standing by, and welcome to the Kiniksa Pharmaceuticals Third Quarter 2026 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you'll need to press star one one on your telephone. If your question has been answered and you'd like to remove yourself from the queue, simply press star one one again. As a reminder, today's program is being recorded. Now I'd like to introduce your host for today's program, Jonathan Kirshenbaum, Investor Relations. Please go ahead, sir. Jonathan KirshenbaumSenior Manager of Investor Relations at Kiniksa Pharmaceuticals International00:00:35Thank you, operator. Good morning, everyone, and welcome to the Kiniksa Pharmaceuticals Third Quarter 2026 Earnings Call. A press release highlighting our financial results and recent portfolio execution can be found on our website under the Investors section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. Jonathan KirshenbaumSenior Manager of Investor Relations at Kiniksa Pharmaceuticals International00:00:58From there, Ross Moat, our Chief Operating Officer, will provide an update on ARCALYST commercial execution. After that, Mark Ragosa, our Chief Financial Officer, will review our third quarter 2026 financial results. Finally, Sanj will return at the end of the call to share closing remarks and kick off the Q&A session, for which John Paolini, Kiniksa's Chief Medical Officer, will also be on the line. Jonathan KirshenbaumSenior Manager of Investor Relations at Kiniksa Pharmaceuticals International00:01:26Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from such statements. A review of these statements and risk factors can be found on this slide, as well as under the caption Risk Factors contained in our SEC filings. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements except as required by law. With that, I'll turn it over to Sanj. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:01:57Thanks, Jonathan, and good morning or good afternoon, everyone. Over the last 10, 11 years, we've built this company through multiple stages of growth, and today, I'm as excited as ever about what the team and I can accomplish together in the years ahead. Kiniksa continues to build a leading IL-1 alpha and beta inhibition franchise driven by the commercialization of ARCALYST in recurrent pericarditis, as well as our progress with KPL-387 and KPL-1161. This morning, we announced via a press release that we've raised our full-year revenue guidance to between $1.045 billion and $1.050 billion. We continue to see robust growth with ARCALYST in recurrent pericarditis, driven by strong execution and strategic investments across the business. On the clinical side, we're excited about the progress of KPL-387 and KPL-1161. The pivotal phase III study with KPL-387 continues to enroll and dose patients. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:03:13We announced today that we expect data from this trial in the second half of 2027. The team and I are really looking forward to potentially launching this drug in the 2028, 2029 timeframe. In addition to providing an important treatment option for patients with recurrent pericarditis, we believe KPL-387 could help grow the market by enabling a once-monthly subQ dosing. We are also on track to have KPL-1161, our quarterly IL-1 alpha and beta inhibitor, in a phase I clinical trial by the end of this year. Importantly, Kiniksa's robust financial profile allows us to continue to invest in penetrating the recurrent pericarditis market and growing the IL-1 alpha and beta inhibition franchise whilst also pursuing additional value-creating opportunities. In the third quarter, we saw a continuation of strong ARCALYST momentum with Q3 revenue of $286 million. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:04:26The penetration rate into the annual population of 14,000 multiple recurrence patients increased to 23% as of the end of Q3. As shown by the increased breadth and depth of prescribing over time, adoption of IL-1 alpha and beta inhibition continues to expand among the approximately 40,000 recurrent pericarditis patients each year. The underlying fundamentals that propelled our commercial success remain strong. Since launch, we have observed robust payer approval, strong patient compliance, and greater appreciation of the need to treat throughout the multi-year duration of the disease. Underpinning this growth is strong execution by our commercial organization and data-driven investments in ARCALYST. Our AI-supported patient identification initiatives and targeted direct consumer campaign, Heart's Home, have positively contributed to growing patient and physician awareness of recurrent pericarditis and the important role of IL-1 alpha and beta inhibition in controlling this debilitating disease. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:05:56As you have heard, we now expect ARCALYST to achieve over $1 billion in revenue in 2026 and we look forward to continuing to bring this blockbuster drug to more patients suffering from this debilitating disease. In order to grow the recurrent pericarditis market over the next several years, we plan to drive greater adoption in both the 14,000 multiple recurrence patients annually and the additional 26,000 patients annually that are experiencing their first recurrence. Kiniksa is executing against its strategy to help more patients drive more ARCALYST growth and advance KPL-387 and KPL-1161. This trajectory will help put the company on a path to having multiple commercial products, continued strong and profitable growth, and the flexibility to invest in future value creation. I can tell you that the team and I will not rest until we have helped many, many more patients. Now our President and COO, Ross Moat. Ross MoatCOO at Kiniksa Pharmaceuticals International00:07:17Thank you, Sanj. As you have heard, we are pleased with the continued strength of our commercial performance with ARCALYST, and we are even more excited by the substantial growth opportunity ahead. We continue to be highly focused on further increasing the penetration rate into the many thousands of recurrent pericarditis patients and continuing to evolve the treatment paradigm towards interleukin-1 alpha and beta inhibition. As illustrated on the left side of this slide, physicians continue to report an increasing consideration of ARCALYST earlier in the disease course, including at the first recurrence. Additionally, we also see a growing appreciation for ARCALYST to be utilized earlier in the line of therapy, meaning after NSAIDs and colchicine, and importantly, prior to corticosteroids, as ratified in the 2025 American College of Cardiology Concise Clinical Guidance for Recurrent Pericarditis. Ross MoatCOO at Kiniksa Pharmaceuticals International00:08:24In fact, approximately 50% of physicians surveyed now support this treatment approach, representing a doubling from levels over the last three years prior to the publication of this independent guidance. As we continue to build and lead this market, our team are laser-focused on value-driven investments that aim to increase market penetration and help many more patients. Increasing education and awareness on recurrent pericarditis, ARCALYST, and the new treatment paradigm remain critical components of our strategy, and we've enhanced our capabilities through the use of AI and machine learning to reach a larger audience. On the healthcare professional side, we've done this through improving our data sources to inform us not only which healthcare professionals we should be seeing, but importantly, when we should be seeing them. On the patient side, we've seen encouraging early indicators from our Heart's Home direct-to-consumer campaign. Ross MoatCOO at Kiniksa Pharmaceuticals International00:09:37Based on this initial traction, we plan to expand the campaign with additional content and outreach initiatives aimed at empowering more patients to engage with their healthcare professionals about ARCALYST. As a reminder, Heart's Home is a highly targeted DTC campaign where we've innovated from traditional DTC by using AI to produce and deliver a campaign that's effective for a rare disease audience. This campaign is aimed at educating an enriched population of likely recurrent pericarditis patients who are currently not taking ARCALYST and empowering them to discuss ARCALYST with their healthcare provider. As an early indicator of the impact of this campaign, we've seen a twelvefold increase in the traffic to our ARCALYST website compared to baseline levels prior to the campaign. Additionally, there's been an eightfold increase with engaged sessions, meaning visits where the individual spends meaningful time on the website or interacts with the content. Ross MoatCOO at Kiniksa Pharmaceuticals International00:10:51More importantly, approximately 55% of patients who saw the ad strongly agreed that they are motivated to speak with their healthcare provider about ARCALYST. All of these indicators are strong signals that our digital strategy is reaching the right audience and is empowering action. As this disease has a very high annual incident rate of patients coming into the labeled indication, this DTC initiative is nicely supplementing our robust execution in the field and helps us to address the substantial opportunity that we have ahead to help many more patients. As previously mentioned, our interleukin-1 alpha and beta inhibition franchise is growing, is profitable, and has significant opportunity in the months and years ahead. With that, I'll turn the call over to Mark to review our financial results. Mark RagosaCFO at Kiniksa Pharmaceuticals International00:11:56Thanks, Ross. Our third quarter delivered continued ARCALYST sales growth, advancement of KPL-387 and KPL-1161 development, and a solid financial position. This morning, I'll review our financial results and key performance drivers. Mark RagosaCFO at Kiniksa Pharmaceuticals International00:12:12Detailed financial information is available in today's press release. Starting with the income statement, ARCALYST revenue grew 58% year-over-year to $286 million in the third quarter, driven by continued gains in patient and physician adoption. Operating expenses increased year-over-year, driven by higher ARCALYST revenue, which resulted in additional cost of goods sold and collaboration expenses, advancement of KPL-387 development, which drove additional R&D investment, and support of ARCALYST commercialization to reach more patients, which led to additional SG&A investment. Operating income rose to $54.2 million and net income to $47.3 million, both up significantly year-over-year. Turning to the calculation of ARCALYST collaboration profit, which drives total collaboration expenses on our income statement. ARCALYST collaboration profit increased 67% year-over-year to $211.6 million, outpacing sales growth and reflecting disciplined commercial investment. Mark RagosaCFO at Kiniksa Pharmaceuticals International00:13:20Next, we ended the third quarter with $568.8 million in cash, reflecting approximately $43 million in net cash generation during the quarter. Looking ahead, in addition to our updated 2026 ARCALYST sales guidance of $1.045 billion-$1.050 billion, we are providing full year R&D and SG&A expense guidance. We expect full year R&D expenses of $160 million-$170 million in 2026. This range includes continued development of KPL-387 and KPL-1161, as well as significant fourth quarter KPL-387 pre-commercial manufacturing costs. We expect full year SG&A expenses of $270 million-$280 million in 2026. This range supports continued ARCALYST commercialization, including additional personnel and promotional activities in the fourth quarter to further build disease awareness and enhance patient and physician targeting. Mark RagosaCFO at Kiniksa Pharmaceuticals International00:14:28In closing, our third quarter results show the strength of our operating plan, a growing and profitable ARCALYST business funding the advancement of key development assets and positioning us to create value in the near and long term. With that, I'll turn the call back to Sanj for closing remarks. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:14:47Thanks, Mark. As you've heard, Kiniksa is jolly well positioned to build significant future value as we grow our IL-1 alpha and beta inhibition franchise. The team and I are on it and focused on helping as many patients as possible with ARCALYST and to advancing the development of our clinical portfolio in order to bring additional therapies to patients. With that, I'll turn it back to the operator for questions. Thank you. Operator00:15:19Certainly. Thank you. Our first question for today comes from the line of Anupam Rama from JPMorgan. Your question, please. Anupam RamaAnalyst at JPMorgan00:15:28Hey, guys. Thanks so much for taking the question, and congrats on the quarter. I just wanted to ask a quick KPL-387 question. I think the guidance for pivotal data in the second half of 2027 is new today. Can you tell us what you're seeing in terms of enrollment dynamics and where you are on site initiation that give you confidence to laying out this timeline? Thanks so much. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:15:52Thanks, Anupam. I think I'll have John Paolini answer that. Suffice to say that our execution, across not just commercial but also the clinical development organization, as I've said before, we are enrolling and dosing patients. It's a global clinical study with global sites, and both myself, John, and Ross take pride in meeting with investigators and just getting them excited about the future. There's been some massive momentum, both internally and with our investigators. As with everything, we go at things with full force, and that's why the guidance is as well and is having results in the second half of next year. John? John PaoliniChief Medical Officer at Kiniksa Pharmaceuticals International00:16:30Yeah, I think that's excellent guidance from Sanj. The only thing that I would add is that on clinicaltrials.gov, you can see the extent of the global nature of our program. The sites that are involved in the program across the world are all listed there. You can see the scope of effort. As Sanj mentioned, we are on the ground and engaging with clinicians, and we can feel the excitement about the program, and so we continue forward. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:16:59I'll also say we have a crack clinical operations team, and having run clinical operations for many years at Genzyme before I ran commercial, I've got a very high bar for clinical research and clinical operations. And after many, many years, I feel like we've really got the best team to do the job. Anupam RamaAnalyst at JPMorgan00:17:20Thanks so much for taking our question, and congrats again on the quarter. Operator00:17:24Thank you. Our next question comes from the line of Edward Nash from Canaccord Genuity. Your question, please. Edward NashAnalyst at Canaccord Genuity00:17:31Hey, good morning, guys. Really excited to see that over $1 billion number now for the guidance. So congratulations. I just wanted to ask now, you're at 23% active penetration. That's 2% higher than last quarter, which is really, I think, impressive. Can you maybe give us an idea of how we should think about the shape of the penetration curve from here? Is there anything structurally different about the next quartile of patients versus the patients you've already converted? You're going up on the SG&A number, which makes a lot of sense, and you've put a lot of focus on the DTC campaign, which clearly seems to be paying off. Just curious as to how many extra dollars need to be put in to achieve greater uptake of scripts? Ross MoatCOO at Kiniksa Pharmaceuticals International00:18:17Thanks, Edward. This is Ross. Thanks very much for your comments. We are pleased to announce that we were around 23% at the end of the quarter in terms of penetration into the multiple recurrence group, which is the patients that have suffered for two or more recurrences, and that is without allocating anything to the first recurrence group, which we have about 20% of our prescriptions in the first recurrence group also. The opportunity is very significant. While on one hand, we are happy with the 23%, and that is obviously showing a couple of percent growth versus the end of Q2 number when we shared it the time before that. The last time we shared the penetration number, I think it was at the end of Q4, which was 18% at the end of last year. Ross MoatCOO at Kiniksa Pharmaceuticals International00:19:01That has been growing relatively nicely, but I think more importantly is the opportunity that is ahead. Clearly there are a lot of patients in the two-plus recurrence group that we have still got to help. As I said, not allocating for even those who are in the first recurrence. As we shared from some of the market research today, the propensity and the desire for physicians to look and treat patients with IL-1 alpha beta inhibition in the first group has also been growing quite substantially over time. We think the future is very bright from that perspective. In terms of different patient groups, aside from the recurrence number, there is really not much else to report. We are not seeing significant change necessary in the demographics of the patients or severity levels or anything else. It is just that this is a rare flaring cardiovascular disease. Ross MoatCOO at Kiniksa Pharmaceuticals International00:19:54There are a lot of patients out there relative to a rare disease. We are trying to get out and reach as many patients as possible. We know that they are widely dispersed around the country, and that takes a certain effort, as you have alluded to, from our sales and marketing spend and so on. Our efforts are ultimately on value-driven investments that can make sure we reach those physicians and switch more and more of them on to this new way of treating and ultimately get greater penetration into this opportunity to ultimately help more patients. Edward NashAnalyst at Canaccord Genuity00:20:34Thanks a lot for that additional coloring. I am sorry, go ahead. Ross MoatCOO at Kiniksa Pharmaceuticals International00:20:38Yeah. No, Edward, maybe just to add the final part as well is that the DTC spend and field team spend that we have, and we've announced in our guidance looking forward as well, is ultimately very efficient. We are very focused on this as a rare disease market. For the DTC side of things, this is not broad-spectrum, massive spend DTC. It's very efficient, very targeted type of expenditure to address appropriately the market that we have. Edward NashAnalyst at Canaccord Genuity00:21:09Great. Thanks for that additional color and really great quarter. Thanks again. Congratulations. Operator00:21:16Thank you. Our next question comes from the line of Paul Choi from Goldman Sachs. Your question, please. Paul ChoiAnalyst at Goldman Sachs00:21:24Hi, everyone. Congratulations on the great quarter and congrats, Ross, as well on the new title. I want to ask on the 387 switch strategy. I was wondering if you could just sort of provide a little more color on where you are with progress on that, and I guess what the ultimate data you're looking for there to support 387 from an insurance perspective. My second question is on 1161. Maybe just where are you thinking in terms of indication selection, I guess, at this point, and a little bit more on the criteria that you're considering for the first indication there for 1161. Thank you so much. John PaoliniChief Medical Officer at Kiniksa Pharmaceuticals International00:22:10Thank you, Paul. Appreciate your questions. This is John. With regard to the KPL-387 transition to monotherapy dosing and administration study, this study is designed primarily as what we call a posology study. It covers dosing administration specifically for informing the label. It's designed, as you can see in the slides, we're looking at how patients are coming from stable therapies, whether they're oral or biologic, and then transitioning to KPL-387 monotherapy at the 300 mg subcutaneous monthly dose level. That's really what that study is designed to do. It follows very similarly the precedent of what's in the ARCALYST label, which similarly describes the transitions from NSAIDs, colchicine, corticosteroids, and anakinra. This is just really following in that tradition. That's how the study is designed and the data that will be generated. John PaoliniChief Medical Officer at Kiniksa Pharmaceuticals International00:23:10I'll turn it over to Ross to talk about ultimately other elements of transition. Ross MoatCOO at Kiniksa Pharmaceuticals International00:23:16Yeah. Thanks very much, John. I guess just to say that obviously we're very excited about the potential for KPL-387. Everything's data dependent as we move forward. When we tested the target product profile for KPL-387, both with healthcare professionals and patients, we were really very encouraged by the feedback that we had back. While we believe that ARCALYST has a lot of growth left in it to address the recurrent pericarditis opportunity, with KPL-387, patients did tell us that around 75% of them would prefer the KPL-387 target profile being a monthly liquid formulation, potentially auto injector over current commercial or other investigational therapies. They also reported a propensity for a greater number of patients to start on therapy with that target product profile, as well as staying on therapy longer. Ross MoatCOO at Kiniksa Pharmaceuticals International00:24:14When you looked at the healthcare professional side, 92% of healthcare professionals indicated a high likelihood to prescribe KPL-387 with that target product profile over available commercial or other investigational therapies. That I think reads quite positively about the future, but ultimately we are focused on conducting the clinical research and awaiting the data. John PaoliniChief Medical Officer at Kiniksa Pharmaceuticals International00:24:42With regard to your question about KPL-1161, we are very excited about this program, which has the potential for once quarterly dosing, again, targeting the IL-1 alpha and beta signaling by targeting the receptor. This program we expect to begin a phase I program by the end of the year. To that extent, we have not yet announced or disclosed our plans with regard to development indications. Suffice it to say, though, that with that longer duration of action, that really unlocks a lot of potential for disease states, especially those that are chronic or lifelong in nature by virtue of the once quarterly dosing. Ross, anything to add? Ross MoatCOO at Kiniksa Pharmaceuticals International00:25:33No. That is great, John. Thank you. Paul ChoiAnalyst at Goldman Sachs00:25:34That is great. Operator00:25:38Thank you. Our next question comes from the line of Roger Song from Jefferies. Your question, please. Peter ChenAnalyst at Jefferies00:25:46All right. This is Peter. I am calling in for Roger. Congrats on a good quarter, and thanks for taking our questions. Just a couple quick ones from us. For Q3, can you tell us what share of the new patients came from first-time versus repeat prescribers? Can you also share whether or how much growth you have seen within the first recurrence patients as well for this quarter? Ross MoatCOO at Kiniksa Pharmaceuticals International00:26:10Yeah, Peter, thanks very much for the questions. We do not share some of that data directly externally, but of course it is the type of thing that we look at a lot internally in the business. What we have shared is in the Q3, clearly we have seen a substantial uplift in the number of patients representing the strong growth of nearly $42.5 million quarter-on-quarter. Ultimately, that is driven by strong prescriber growth. What we have said is that when you look at the total number of prescribers launched to date of ARCALYST for recurrent pericarditis in Q3, or I should say at the end of Q3, we had around 5,450 total prescribers. That is an uplift of around 450 quarter-on-quarter. Again, it is really showing very strong growth. Ross MoatCOO at Kiniksa Pharmaceuticals International00:27:01Now we have around 30% of that group who are repeat prescribers, which is up by around 170 prescribers. Historically, we have said that the split between the first and second recurrence is about 80% of prescriptions in the second plus recurrence and 20% in the first, but we have not updated that data on a very frequent basis, as a lot of it comes from kind of ad hoc market research that we do. Clearly we are showing pretty strong growth in Q3. A lot of that is down to the refined targeting that we have with our field team, the DTC campaign in a very targeted approach, and also just broader dissemination of the ACC concise clinical guidance and really just empowering physicians on this new way of treating the disease. Peter ChenAnalyst at Jefferies00:27:51Got it. Thanks so much for the additional color and congrats again on the quarter. Ross MoatCOO at Kiniksa Pharmaceuticals International00:27:55Thanks, Peter. Operator00:27:57Thank you. Our next question comes from the line of Geoff Meacham from Citi. Your question, please. Geoff MeachamAnalyst at Citi00:28:04Hey, guys. Great job on the quarter. Thanks for the question. Just have a couple quick ones. The first on 387, I know convenience angle obviously is a big differentiator, but beyond that, is there a patient maybe on ARCALYST today that you think is particularly suited to transition to 387 just beyond convenience? I know clinically maybe those that live further away or what are the attributes of the patients, I guess is the question that would maybe more rapidly switch? Then bigger picture question, just on the cash and the capital deployment. You guys have been consistently profitable. You are building some cash on the balance sheet. I do not know, just trying to think of ways to maximize value from a balance sheet cash flow context. What are you thinking about from a BD perspective? Where does this fall in your priorities? Thank you. John PaoliniChief Medical Officer at Kiniksa Pharmaceuticals International00:29:07Thank you, Geoff, for your question. I will tackle this first part with regard to the transition, if you will, from ARCALYST to KPL-387. I think that our position with regard to the management of the disease is that blockade of IL-1 alpha and IL-1 beta is critical to maintaining disease control and to gaining the disease control as a monotherapy. In that sense, we are particularly excited about the KPL-387 program because it adds to the optionality of what is available to patients and physicians in terms of treating this disease. That efficacy ultimately remains to be demonstrated in the phase III pivotal trial, which is ongoing. John PaoliniChief Medical Officer at Kiniksa Pharmaceuticals International00:29:52But importantly, what we have going on as well is the 212 study or the KPL-387 transition to monotherapy dosing and administration study, which is really designed to look at the mechanics of how to transition from one existing therapy to KPL-387 monotherapy at the 300 mg monthly dose level. That includes NSAIDs and colchicine, corticosteroids or IL-1 pathway inhibitors, including anakinra and rilonacept. All of those different transition regimens are studied and are evaluated in the study and then go on to over a 16-week primary endpoint period. So it's really about that transition, and that then informs the label with regard to telling or informing physicians how they can make that transition. In terms of the patient profile, it's really about the optionality for the patient and the physician to choose which effective therapy is considered to be best for them. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:31:00Geoff, in regards to your question on maximizing value and cash position, I can tell you what drives us each and every day is the potential to increase that overall maximum value. There's so much kinetic energy within the company that's focused on that. We've talked about, obviously today, the growth with ARCALYST, and we continue to be very excited about the future potential there. We talked about the latest penetration rate at being, in some ways, only 23%. Equally, obviously, across the development portfolio with KPL-387 and 1161, as we've talked about, really moving now into what obviously is a phase III pivotal study for 387, being very excited about being in the clinic with 1161 later this year. As you see, those latter two programs were homegrown. So we continue to look at other additional value-creating opportunities, both internally but also externally. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:31:51I think we've been very judicious and very thoughtful about capital allocation. We do look at BD opportunities, but as you can imagine, with our commercial products, with our pipeline, the bar is exceedingly high. That said, we're a very pragmatic bunch, and we do look at where the value could come from all the time. It's what drives us, essentially. So rest assured, we know how to capital allocate. We know where best to drive value, and we'll continue doing that and ultimately keep executing. Geoff MeachamAnalyst at Citi00:32:22Great. Thank you. Operator00:32:24Thank you. This does conclude the question and answer session of today's program. I would like to hand the program back to Sanj K. Patel, CEO, for any further remarks. Sanj K. PatelCEO at Kiniksa Pharmaceuticals International00:32:34Thank you very much. Thanks, everybody, for dialing in today. Clearly a lot of excitement, ongoing execution, and very excited about the future. The team and I will keep driving for future success for patients and for creating that additional value. Thank you. Operator00:32:49Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.Read moreParticipantsExecutivesJonathan KirshenbaumSenior Manager of Investor RelationsSanj K. PatelCEORoss MoatCOOMark RagosaCFOJohn PaoliniChief Medical OfficerAnalystsAnupam RamaAnalyst at JPMorganEdward NashAnalyst at Canaccord GenuityPaul ChoiAnalyst at Goldman SachsPeter ChenAnalyst at JefferiesGeoff MeachamAnalyst at CitiPowered by